Omega-3 Fatty Acids: EPA, DHA, and the Inflammation Connection

What Are Omega-3 Fatty Acids?

Omega-3 fatty acids are a family of polyunsaturated fats characterized by a double bond at the third carbon from the omega end of the fatty acid chain. They are considered essential fatty acids — meaning the human body cannot synthesize them in adequate amounts and must obtain them through diet or supplementation.

The three primary omega-3s relevant to human health are:

• ALA (Alpha-linolenic acid): The plant-derived omega-3 found in flaxseed, chia seeds, walnuts, and hemp. ALA is the precursor to EPA and DHA, but conversion in humans is inefficient — typically less than 5–10% for EPA and under 1% for DHA.
• EPA (Eicosapentaenoic acid): A marine-derived omega-3 with potent anti-inflammatory effects, primarily found in fatty fish and fish oil. EPA is the primary substrate for anti-inflammatory eicosanoids and resolvins.
• DHA (Docosahexaenoic acid): The structural omega-3, comprising approximately 40% of the polyunsaturated fatty acids in the brain and 60% in the retina. DHA is critical for neurological development, cognitive function, and visual acuity throughout life.

The Inflammation Connection

Chronic low-grade inflammation is the common thread underlying cardiovascular disease, type 2 diabetes, obesity, neurodegenerative disease, autoimmune conditions, and cancer. Omega-3 fatty acids — particularly EPA and DHA — are among the most well-studied nutritional modulators of the inflammatory cascade.

The mechanisms are multiple and well-characterized:

• Eicosanoid competition: EPA and DHA compete with arachidonic acid (AA, an omega-6) for the same enzymes (COX and LOX). AA-derived eicosanoids (prostaglandins, leukotrienes) are pro-inflammatory; EPA-derived eicosanoids are far less inflammatory or anti-inflammatory.
• Specialized pro-resolving mediators (SPMs): EPA and DHA are converted into resolvins, protectins, and maresins — a class of lipid mediators that actively resolve inflammation rather than simply suppressing it.
• NF-κB inhibition: Omega-3s suppress nuclear factor kappa B (NF-κB), the master transcription factor that drives production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.
• Cell membrane incorporation: EPA and DHA incorporate into cell membranes, altering membrane fluidity, receptor function, and lipid raft composition — affecting inflammatory signaling at the cellular level.

Clinical Evidence: What the Research Shows

Cardiovascular Health

• The REDUCE-IT trial (2018) found that high-dose EPA (4g/day as icosapentaenoic acid/Vascepa) reduced major cardiovascular events by 25% in high-risk patients with elevated triglycerides.
• Omega-3s consistently reduce triglycerides by 20–50% at doses of 2–4g/day.
• Meta-analyses support modest reductions in blood pressure and improvements in heart rate variability.

Brain and Mental Health

• DHA is the dominant structural fat in the brain; low DHA status is associated with accelerated cognitive decline, depression, and increased dementia risk.
• Multiple meta-analyses support EPA supplementation for depression, with effect sizes comparable to antidepressants in some studies.
• Omega-3 supplementation during pregnancy is associated with improved infant neurodevelopment and reduced risk of preterm birth.

Inflammation and Autoimmunity

• Rheumatoid arthritis: Multiple RCTs show omega-3 supplementation reduces joint pain, morning stiffness, and NSAID requirements.
• IBD: EPA and DHA reduce inflammatory markers in Crohn's disease and ulcerative colitis.

Metabolic Health

• Omega-3s improve insulin sensitivity, reduce hepatic fat (NAFLD), and lower inflammatory markers in metabolic syndrome.

Omega-3 to Omega-6 Ratio

The ratio of omega-6 to omega-3 fatty acids in the diet is a critical determinant of inflammatory tone. The ancestral human diet likely had an omega-6:omega-3 ratio of approximately 1:1 to 4:1. The modern Western diet has a ratio of 15:1 to 20:1 — driven by the ubiquity of seed oils rich in linoleic acid. Correcting this ratio is a foundational anti-inflammatory dietary strategy.

Food Sources of EPA and DHA

• Fatty fish: Sardines, mackerel, wild salmon, herring, and anchovies.
• Fish roe (caviar): Exceptionally rich in DHA.
• Oysters and mussels: Good sources of EPA and DHA among shellfish.
• Algae oil: The preferred vegan/vegetarian source.

Supplementation: Choosing and Dosing

• Dose: 1–2g/day of combined EPA+DHA for general health; 2–4g/day for therapeutic applications.
• Form: Triglyceride (TG) form is better absorbed than ethyl ester (EE) form. Algae oil is the cleanest vegan option.
• Quality: Look for third-party testing (IFOS certification) and molecular distillation to remove heavy metals and PCBs.

Safety Considerations

• At doses above 3g/day, omega-3s have mild blood-thinning effects; consult a physician if on anticoagulants.
• Oxidized (rancid) fish oil may be pro-inflammatory — quality and storage matter.

The Bottom Line

EPA and DHA are among the most evidence-supported nutritional interventions in medicine, with robust data across cardiovascular health, brain function, inflammation, and metabolic disease. Whether through regular consumption of fatty fish or high-quality supplementation, optimizing omega-3 status is one of the highest-leverage nutritional interventions available.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning supplementation, especially if you are on medications.

Related Articles

• Metabolic Flexibility: Fat vs. Glucose as Fuel
• The Gut Microbiome: How to Build and Protect It
• Protein Optimization: How Much, What Kind, and When
• Fiber: The Overlooked Pillar of Metabolic Health